PCI Biotech Holding ASA

PCI Biotech Holding ASA is a biopharmaceutical company that develops technologies and novel therapies through its photochemical technology platform. The platform consists of a proprietary small molecule photosensitiser and a light source. The company develops photochemical lysis (PCL), a light-triggered cell lysis that enhances yield and purity in viral vector manufacturing, and photochemical internalisation (PCI), which induces light-triggered intracellular release for various therapeutic modalities. It also explores intratumoural immunotherapy therapeutics aimed at identifying novel treatment combinations to overcome resistance to immune-checkpoint inhibitors and safety issues associated with treatments, and develops nucleic acid therapeutics to improve the treatment of dermatological diseases. PCI Biotech Holding ASA was incorporated in 2007 and is headquartered in Oslo, Norway.